NCT06572839 is a NA clinical trial of Amnio-Maxx in Diabetic Foot Ulcer, sponsored by Capsicure, LLC.

Who is sponsoring NCT06572839?

NCT06572839 is sponsored by Capsicure, LLC.

What drugs are being tested in NCT06572839?

Interventions in NCT06572839: Amnio-Maxx.

What condition does NCT06572839 study?

NCT06572839 studies Diabetic Foot Ulcer.

Is NCT06572839 still recruiting?

NCT06572839 is currently recruiting now. Last updated 30 April 2025.

Last reviewed 2025-04-30 · How we verify

NCT06572839

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

Recruiting now NA Last updated 30 April 2025

What this trial tests

NA trial testing Amnio-Maxx in Diabetic Foot Ulcer in 150 participants. Currently enrolling.

Timeline

25 October 2024

Primary endpoint
31 October 2025

31 October 2025

Quick facts

Lead sponsor	Capsicure, LLC
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	25 October 2024
Primary completion	31 October 2025
Estimated completion	31 October 2025
Sites	12 locations across United States

Drugs / interventions tested

Amnio-Maxx

Conditions studied

Diabetic Foot Ulcer — all drugs for Diabetic Foot Ulcer →

Sponsor

Capsicure, LLC

Who can join

18 and older, any sex, with Diabetic Foot Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled study evaluates the adjuvant use of Amnio-Maxx in patients with diabetic foot ulcers

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetic Foot Ulcer

Currently open trials in the same condition.

NCT07161830 — Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers · NA · recruiting
NCT07396376 — Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers · Phase 1, PHASE2 · recruiting
NCT07291817 — Intermittent Negative Pressure for Patients With Diabetic Foot Ulcers (INPRESS) Study · NA · recruiting
NCT07209358 — EDX110 Randomized Control Trial for Treatment of DFUs · NA · recruiting
NCT06938685 — Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers · NA · recruiting

Other Capsicure, LLC trials

Trials by the same sponsor.

NCT07046767 — CAMP RWE Trial: Amnion Grafts for Healing Hard-to-Heal Ulcers in RW Populations · NA · recruiting
NCT06455475 — Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06572839 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Capsicure, LLC
Last refreshed: 30 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06572839.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing